Chronotherapy in Acute Multiple Sclerosis (MS) Attack
Status:
Terminated
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The Immunological system is showing a diurnal rhythmicity. The Mediators that enhances
inflammation are at highest level during the night. At the same time the endogenous
production of cortisol is at its lowest. We want to study if there is a better effect of
treatment with Methylprednisolone for acute MS-attacks if given at nighttime. The effect will
be measured in relation to neurological deficits and function with Kurtzkes Expanded
Disability Status Score (EDSS) and Multiple Sclerosis Functional Composite (MSFC). We want to
see if the mean improvement in EDSS is greater in the group receiving treatment at night
opposed to the group that get treatment during the daytime.